Cyclana Bio raised £5 million in a pre‑seed round co‑led by NfX and Eka Ventures to develop a tissue‑level platform for identifying drug targets and functional disease models, initially focusing on endometriosis. The Cambridge‑based startup plans to use menstrual fluid and tissue modeling to discover early biomarkers and therapeutic leads. Founders said the platform integrates extracellular‑matrix biology with molecular and computational tools to reveal disease mechanisms where they originate — the tissue microenvironment. Cyclana characterized the raise as seed capital to build assays, expand sample collection and advance target validation. The financing underscores renewed investor interest in women’s‑health focused biotech and tissue‑first discovery strategies that aim to shorten translational pathways.